Larvol Delta - Study-of-Trastuzumab-Deruxtecan-TDXd-in-Combination-With-a-RAGE-Inhibitor-in-Patients-With-TDXdResistant-HER2Positive-or-HER2Low-Metastatic-Breast-Cancer

azeliragon (TTP488) - Cantex Pharma

Enhertu (fam-trastuzumab deruxtecan-nxki) - Daiichi Sankyo, AstraZeneca

http://clinicaltrials.gov/ct2/show/NCT07785856

Aug 26, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next